Table 4.
Distribution of treatment after kidney biopsy according to the levels of vitamin D metabolites in glomerular diseases
| 25(OH)D | 1,25(OH)2D | |||||||
|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T3 | P | T1 | T2 | T3 | P | |
| RAS blockers | 0.35 | 0.23 | ||||||
| No | 11(19.0) | 8(13.8) | 4(7.0) | 11(19.0) | 6(10.3) | 6(10.5) | ||
| Yes (Before biopsy) | 14(24.1) | 12(20.7) | 17 (29.8) | 16(27.6) | 17(29.3) | 10(17.5) | ||
| Yes (After biopsy) | 33(56.9) | 38(65.5) | 36(63.2) | 31(53.4) | 35(60.3) | 41(71.9) | ||
| Immmunosuppressive agents | 0.61 | <0.001 | ||||||
| No | 32(55.2) | 42(72.4) | 42(73.7) | 31(53.4) | 34(58.6 | 51(89.5) | ||
| Yes | 26(44.8) | 16(29.8) | 15(26.3) | 27(46.6) | 24(41.4) | 6(10.5) | ||
Abbreviations: 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)2D: 1,25-dihydroxyvitamin D; RAS: renin-angiotensin system; T: tertile